Detalhe da pesquisa
1.
Reweighting estimators to extend the external validity of clinical trials: methodological considerations.
J Biopharm Stat
; 33(5): 515-543, 2023 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36688658
2.
Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
Rheumatology (Oxford)
; 60(9): 4367-4372, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33479721
3.
On the design and the analysis of stratified biomarker trials in the presence of measurement error.
Stat Med
; 40(12): 2783-2799, 2021 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33724513
4.
Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis.
Clin Exp Rheumatol
; 39(2): 329-336, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32573426
5.
A comparison of reweighting estimators of average treatment effects in real world populations.
Pharm Stat
; 20(4): 765-782, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33675139
6.
Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
Clin Exp Rheumatol
; 38(6): 1227-1230, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452352
7.
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
J Am Acad Dermatol
; 82(4): 927-935, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31712178
8.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
; 83(3): 839-846, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344071
9.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res
; 29(2): 369-380, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655974
10.
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
J Drugs Dermatol
; 19(8): 741-746, 2020 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32845588
11.
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.
Ann Rheum Dis
; 78(9): 1215-1219, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31113794
12.
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.
Clin Exp Rheumatol
; 37(4): 566-574, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30557128
13.
Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/ß-Catenin Signaling Pathway in Glioma Cells.
Int J Mol Sci
; 20(3)2019 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30678307
14.
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
Rheumatology (Oxford)
; 57(10): 1777-1788, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945203
15.
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.
J Sex Med
; 15(11): 1645-1652, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415816
16.
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
Acta Derm Venereol
; 98(1): 98-102, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28929168
17.
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
BMC Dermatol
; 18(1): 4, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954363
18.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Ann Rheum Dis
; 76(1): 79-87, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27553214
19.
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis.
Health Qual Life Outcomes
; 15(1): 239, 2017 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29212515
20.
Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis.
Health Qual Life Outcomes
; 15(1): 237, 2017 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29208004